Global Dental Devices, Dental Implants And Dental Diagnostic Devices Market Through 2020
M2 - Tue Dec 16, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/tcpwzv/global_dental) has announced the addition of the "Global Dental Devices, Dental Implants And Dental Diagnostic Devices Market Through 2020" report to their offering. The global dental market comprises dental implants, dental prosthesis, dental biomaterials, dental crowns and bridges, dental imaging, dental units and equipment. In the past decade, the market has experienced a swelling expansion due to a surge in the uptake of implants, crowns and cosmetic dentistry. The key factors igniting the market growth include poor oral hygiene, a rise in incidences of oral diseases on the back of a growing elderly population, an improvement in oral care needs of individuals and an increasing disposable income in developing economies. The acceptance and proliferation of technology in terms of dental imaging (3D imaging), design and manufacturing (CAD/CAM) has resulted in better diagnosis, dental designs, patient compliance and a decrease in chair time. Globally, the US is the leading market for dental care devices with its Centers for Medicare and Medicaid Services (CMS) having estimated the demand for dental services in the country to approach $167 billion by 2015. As per The Association of Dental Dealers of Europe (ADEE), in 2011, the European dental market increased by 1.2% in terms of the total turnover for all countries with the number of active dentists increasing slightly by 0.8%. Another key market is the Asia-Pacific region. Japan is a relatively mature market in the APAC region, whereas in developing countries like India and China, rising disposable income of the middle class as well as growing dental-care awareness and consumer acceptance are contributing to market growth. Companies Mentioned - A-Dec Inc. - Biolase Inc. - Danaher Corporation - GC CORPORATION - Henry Schein Inc. - Midmark Corporation - NAKANISHI INC. - Nobel Biocare - Patterson Dental Supply Inc. - Planmeca Oy - Sirona Dental Systems Inc. - Straumann (SIX) - Sybron Dental Specialties Inc. - Young Innovations Inc. For more information visit http://www.researchandmarkets.com/research/tc...bal_dental
SIRO: 86.04 (+0.29), BIOL: 2.63 (-0.04), DHR: 82.23 (-1.16), HSIC: 132.40 (+0.86)
The Global Dental Device Market to hit $12.7 Billion by 2020 Propelled by a Surge in Oral Diseases and Poor Oral Hygiene: ABMRG
PR Newswire Europe - Tue Dec 09, 7:00AM CST
LONDON and NEW YORK, December 9, 2014 /PRNewswire/ --
SIRO: 86.04 (+0.29), BIOL: 2.63 (-0.04), PDCO: 47.12 (-0.02), SIX: 41.15 (-0.62), DHR: 82.23 (-1.16), HSIC: 132.40 (+0.86)
BIOLASE Launches New EPIC(TM) X diode laser in the United States; Now Dentists Can Delight Their Patients, Faster
PR Newswire - Mon Dec 01, 3:37PM CST
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in lasers, today introduced the EPIC(TM) X diode laser, the company's premier and most complete diode laser for the whole dental team.
BIOL: 2.63 (-0.04)
BIOLASE Introduces a New Commitment to Customer Care, Quality and Innovation at Greater New York Dental Meeting 2014
Business Wire - Fri Nov 28, 11:16AM CST
BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced a variety of advances and activities for the upcoming Greater New York Dental Meeting 2014 including the introduction of a new generation EPIC X diode laser, designed to be the premier and complete diode laser for the whole dental team. The Greater New York Dental Meeting, billed as the largest dental congress and exposition in the U.S., will be held from Friday, Nov. 28-Wednesday, Dec. 3, at the Jacob K. Javits Convention Center in New York City. The Exhibits at the meeting will be open from Sunday, Nov. 30-Wednesday Dec. 3.
BIOL: 2.63 (-0.04)
Biolase CMO bids adieu
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 3:12PM CST
BIOL: 2.63 (-0.04)
Biolase Announces Management Change
Business Wire - Wed Nov 19, 3:05PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today reported that Alexander K. Arrow, M.D. has resigned as Chief Medical Officer and will be leaving the Company effective December 3, 2014 to pursue other opportunities.
BIOL: 2.63 (-0.04)
InsiderInsights.com Daily Round Up 11/6/14: Chimerix, Biolase, Barrett Business Services, Ares Capital
InsiderInsights - at Seeking Alpha - Fri Nov 07, 1:06PM CST
InsiderInsights.com Daily Round Up 11/5/14: ELGX, NS, BIOL, NHF
InsiderInsights - at Seeking Alpha - Thu Nov 06, 3:19AM CST
VR: 40.15 (unch), JBHT: 82.31 (-0.70), FCX: 21.19 (+0.16), BBY: 35.77 (-1.14), NS: 53.82 (+0.40), LL: 60.50 (+0.73), ELGX: 13.93 (+0.18), ENFC: 14.46 (+0.35), RCL: 76.76 (-2.02), LMCA: 33.45 (-0.21), SPW: 77.79 (-0.75), OPK: 8.70 (-0.16), BIOL: 2.63 (-0.04), IMI: 1.97 (-0.02), NHF: 10.69 (-0.05), SIX: 41.15 (-0.62), TWTR: 35.13 (-1.72), SCHW: 28.12 (-0.62)
BIOLASE's (BIOL) CEO Jeff Nugent on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 10:01PM CST
BIOL: 2.63 (-0.04)
Biolase beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:26PM CST
BIOL: 2.63 (-0.04)
BIOLASE Reports 2014 Third Quarter Results
Business Wire - Tue Nov 04, 3:07PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today reported unaudited financial results for the third quarter and nine months ended September 30, 2014.
BIOL: 2.63 (-0.04)
BIOLASE to Raise $35 Million from Institutional and Individual Investors in Private Placement
Business Wire - Tue Nov 04, 12:00PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading dental laser manufacturer and distributor, announced today that investors including Jack W. Schuler, Oracle Partners, L.P. and other Oracle funds, three funds managed by Camber Capital Management, LLC, Eagle Growth Partners I and II, Birchview Capital L.P., Trellus Partners, LP, CAC, LLC, and certain BIOLASE directors, officers, and employees have agreed to purchase $35 million of unregistered shares of the Company's common stock and warrants to purchase unregistered shares of the Company's common stock in a private placement transaction. Under the terms of the private placement, BIOLASE has agreed to sell an aggregate of 14,162,873 shares of its common stock at the price of $2.39 per share, the closing price quoted on NASDAQ on November 3, 2014. In addition, the investors will receive warrants to purchase up to an aggregate of 9,205,862 shares of BIOLASE(R) common stock at an exercise price of $4.00 per share. The warrants become exercisable six months after the closing of the private placement and have a term of three years from the date of issuance.
BIOL: 2.63 (-0.04)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.14 (-0.01), ITRI: 39.59 (+0.27), AWAY: 28.28 (-1.07), OKE: 44.30 (-0.02), HR: 26.73 (-0.01), NYMT: 7.89 (+0.02), OCLR: 1.92 (+0.03), ENPH: 12.46 (+0.08), ADEP: 8.00 (-0.03), CBSO: 27.51 (+0.58), NSTG: 13.56 (-0.25), MITT: 18.13 (-0.76), CRTO: 37.84 (+0.53), FOXA: 36.21 (-0.29), OKS: 38.23 (-0.16), JMBA: 13.39 (-0.18), IVR: 15.31 (-0.18), CSU: 24.03 (-0.29), MYGN: 33.02 (-0.41), JIVE: 5.33 (-0.03), GAS: 50.42 (-0.23), COUP: 15.39 (+0.08), NRP: 9.59 (+1.19), MOSY: 1.65 (-0.03), COHR: 58.60 (-0.05), DOX: 45.78 (-0.12), CKEC: 24.91 (-0.59), OAS: 14.23 (+2.01), PAYC: 26.59 (+2.35), PCYC: 129.56 (+1.12), AXLL: 37.22 (-1.06), NP: 56.01 (-0.32), BIRT: 6.57 (+0.02), ATVI: 19.38 (-0.64), EXAM: 38.20 (-0.96), P: 16.90 (-0.29), JAZZ: 159.65 (-2.95), PBPB: 11.88 (+0.22), EXEL: 1.31 (-0.05), CERS: 4.78 (+0.14), DVN: 54.10 (+1.44), FEYE: 27.72 (-0.84), CHUY: 19.04 (-0.78), FRGI: 55.82 (-4.46), GHDX: 30.54 (+0.01), PACD: 4.46 (-0.04), BIO: 116.03 (+0.28), BIOL: 2.63 (-0.04), JKHY: 61.39 (-0.36), KAR: 33.79 (-0.35), CDXS: 2.28 (-0.04), MPO: 1.42 (+0.26), FANG: 55.84 (+2.44), CORT: 3.09 (+0.12), CALD: 14.76 (unch)
Biolase reports November 4
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 9:12AM CDT
BIOL: 2.63 (-0.04)
BIOLASE(R) to Host Third Quarter Financial Results Conference Call on November 4, 2014
Business Wire - Thu Oct 23, 8:01AM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading dental laser manufacturer and distributor, announced today that the Company will host a conference call on Tuesday, November 4th, at 4:30 p.m. Eastern Time to discuss its operating results for the third quarter and nine months ended September 30, 2014, and to answer questions. A press release disclosing the Company's financial results will be distributed at approximately 4:05 p.m. Eastern Time that same day.
BIOL: 2.63 (-0.04)
George Soros Picks KIOR, RSH, BIOL Soar On Monday
at The Street - Mon Sep 15, 3:43PM CDT
KiOR Inc (NASDAQ:KIOR), RadioShack Corporation (NYSE:RSH) and BIOLASE Inc (NASDAQ:BIOL) are today's top-gaining billionaire stock picks. On the losing end are NII Holdings Inc (NASDAQ:NIHD), dELiA...
ENZN: 1.04 (-0.03), DLIA: 0.01 (unch), BIOL: 2.63 (-0.04), RSH: 0.34 (-0.05)
Dental Equipment Market (Dental Radiology, CAD/CAM, Dental Chairs, Dental Lasers) Current Trends, Opportunities - Global Forecast to 2019
M2 - Thu Sep 04, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h2kw9g/dental_equipment) has announced the addition of the "Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019" report to their offering. The global dental equipment market is expected to reach $7,138.9 million by 2019 from $5,416.3 million in 2014, growing at a CAGR of 5.7% from 2014 to 2019. Dental equipment systems are used for the diagnosis and treatment of oral diseases. These devices help detect abnormalities and diseases such as oral cancer. Factors such as the rising aging population, increasing demand for cosmetic dentistry, and dental tourism drive the growth of this market. Technological advancements, which help in the introduction of new and innovative devices in the market, are another major factor driving the growth of the market. The relatively untapped Asian markets have opened an array of opportunities for the market to grow. However, factors such as lack of reimbursements may restrain the growth of this market. On the basis of products, the dental equipment market is segmented into dental systems and equipment, dental lasers, and dental radiology equipment. The dental systems and equipment market is expected to grow at the highest CAGR. This growth can be attributed to the increasing need for dental services due to the rising aging population and dental tourism. Dental radiology equipment comprises the second largest segment in the market. This segment was further categorized into extraoral radiology, intraoral radiology, and hybrid units. The extraoral radiology segment is expected to grow at the highest CAGR in the dental radiology equipment market. The growth can be attributed to the increasing demand for the cone beam computed tomography (CBCT) systems. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium insights 5 Market Overview 6 Industry Trends 7 Dental Equipment Market 8 Global Dental Equipment Market, By Geography 9 Competitive Landscape 10 Company Profiles - 3M Company - A-Dec, Inc. - Biolase, Inc - Carestream Health, Inc. (A Subsidiary of Onex Corporation) - Danaher Corporation - Dentsply International, Inc. - Ivoclar Vivadent AG - Midmark Corporation - Planmeca OY - Sirona Dental Systems, Inc. For more information visit http://www.researchandmarkets.com/research/h2..._equipment
SIRO: 86.04 (+0.29), MMM: 159.05 (+2.20), BIOL: 2.63 (-0.04), DHR: 82.23 (-1.16)
BIOLASE Names Jeffrey M. Nugent Permanent President and Chief Executive Officer
Business Wire - Tue Sep 02, 8:01AM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today announced that Jeffrey M. Nugent has been named President and Chief Executive Officer by the Company's Board of Directors, effective immediately. Nugent has served as Acting Chief Executive Officer and a member of the Board of Directors since June 2014.
BIOL: 2.63 (-0.04), VRX.TO: 159.38 (-1.78)
BIOLASE Names Alexander K. Arrow, M.D. Chief Medical Officer
Business Wire - Tue Sep 02, 7:45AM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today announced that Alexander K. Arrow, M.D. has been named to the newly-created position of Chief Medical Officer, effective immediately. Dr. Arrow had been the Company's President and Chief Operating Officer since 2013 and was a member of the Board of Directors from 2010 to 2014. In a separate announcement to be made later this morning, the Company will announce the appointment of its permanent President and Chief Executive Officer.
BIOL: 2.63 (-0.04)